| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
|
|---|---|
| References | |
| Additional Infomation |
Hemocyanin from the keyhole limpet is an immunomodulator that can be used as a vaccine to help the body fight cancer. It is a natural protein isolated from the marine mollusc, the keyhole limpet. Hemocyanin is an immunogenic carrier protein that enhances the antigenic immune response to haptens and other weak antigens, such as idiotype proteins, in vivo. (NCI04) Metalloproteins function as oxygen transport proteins in the hemolymph of mollusks and arthropods. They are characterized by two copper atoms coordinated to histidine residues, reversibly binding a single oxygen molecule; they do not contain heme groups.
Pharmacological Indications Studied for the treatment of bladder cancer and solid tumors. Mechanism of Action Keyhole hemocyanin (KLH) is generally a very effective conjugating agent. It is the most commonly used carrier protein in the preparation of hapten conjugates. KLH consists of five subunits. It is rich in lysine and contains a large amount of available primary amines, which promote conjugation, antibody production, and peptide linking after dissociation. |
| Exact Mass |
1020.893
|
|---|---|
| CAS # |
9013-72-3
|
| PubChem CID |
168009928
|
| Appearance |
Off-white to gray solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
54
|
| Heavy Atom Count |
72
|
| Complexity |
898
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCC=CCCCCCCCC(=O)OCC(C)O.CCCCCCCCC=CCCCCCCCC(=O)OC(C)CO.CCCCCCCCC=CCCCCCCC(C)C(=O)OCCO
|
| InChi Key |
NECYLMLMGRVXJM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/3C21H40O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(2)21(23)24-19-18-22;1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21(23)24-19-20(2)22;1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21(23)24-20(2)19-22/h3*10-11,20,22H,3-9,12-19H2,1-2H3
|
| Chemical Name |
2-hydroxyethyl 2-methyloctadec-9-enoate;1-hydroxypropan-2-yl octadec-9-enoate;2-hydroxypropyl octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07473752
Conditions:Phase 1 First-in-human Study Involving Healthy SubjectsLink: https://clinicaltrials.gov/ct2/show/NCT05845996
Conditions:Healthy VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT00019097
Conditions:Stage II Multiple Myeloma|Stage III Multiple Myeloma|Refractory Plasma Cell Neoplasm
Title:Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
Status:Completed
updateDate:2023-12-27
Ctid:NCT00004198
Link: https://clinicaltrials.gov/ct2/show/NCT00004198
Conditions:LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00006478
Conditions:LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00004197
Conditions:LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT02754362
Conditions:Glioblastoma|GliomaLink: https://clinicaltrials.gov/ct2/show/NCT00369291
Conditions:Germ Cell Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell NeoplasmLink: https://clinicaltrials.gov/ct2/show/NCT00282308
Conditions:Rheumatoid ArthritisLink: https://clinicaltrials.gov/ct2/show/NCT00536120
Conditions:Multiple SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT02079480
Conditions:Healthy Adult VolunteersLink: https://clinicaltrials.gov/ct2/show/NCT00093522
Conditions:Kidney CancerLink: https://clinicaltrials.gov/ct2/show/NCT00017290
Conditions:LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00004249
Conditions:Lung CancerLink: https://clinicaltrials.gov/ct2/show/NCT00006034
Conditions:Bladder CancerLink: https://clinicaltrials.gov/ct2/show/NCT00091143
Conditions:Melanoma (Skin)Link: https://clinicaltrials.gov/ct2/show/NCT00003638
Conditions:Breast CancerLink: https://clinicaltrials.gov/ct2/show/NCT00003819
Conditions:Prostate CancerProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
